Impact of the 10-valent pneumococcal non-typeable Haemophilus influenzae Protein D conjugate vaccine (PHiD-CV) on bacterial nasopharyngeal carriage

• Published in: Vaccine Vol. 29; no. 10; pp. 1959 - 1967
• Main Authors: Prymula, Roman, Hanovcova, Irena, Splino, Miroslav, Kriz, Pavla, Motlova, Jitka, Lebedova, Vera, Lommel, Patricia, Kaliskova, Eva, Pascal, Thierry, Borys, Dorota, Schuerman, Lode
• Format: Journal Article
• Language: English
• Published: Kidlington Elsevier Ltd 24.02.2011; Elsevier; Elsevier Limited
• Subjects: acetaminophen; Acquisitions & mergers; Age; Allergy and Immunology; Applied microbiology; Bacteria; Bacteriology; Biological and medical sciences; Booster; Carrier State - prevention & control; descriptive studies; Ear diseases; Female; Fundamental and applied biological sciences. Psychology; Haemophilus Infections - prevention & control; Haemophilus influenzae; Haemophilus influenzae - isolation & purification; Health facilities; Humans; Immunization; Immunization, Secondary - methods; Infant; Male; Meningitis; Microbiology; Miscellaneous; Nasopharyngeal carriage; Nasopharynx - microbiology; paracetamol; Pathogens; Pneumococcal Infections - prevention & control; Pneumococcal Vaccines - administration & dosage; Pneumococcal Vaccines - immunology; Pneumonia; protein D; Proteins; secondary immunization; Serotypes; Streptococcus infections; Streptococcus pneumoniae; Streptococcus pneumoniae - isolation & purification; Tetanus; vaccination; Vaccination - methods; Vaccine; Vaccines; Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects); PP; PCV; DTPa–HBV–IPV/Hib; NTHi; Nasopharyngeal carriage; CI; MenACWY-TT; Booster; Vaccine; 11Pn-PD; POET; Haemophilus influenzae; MEF; NPP; VE; Streptococcus pneumoniae; SD; OMP; OD; PHiD-CV; IPD; AOM; pneumococcal conjugate vaccines; invasive pneumococcal disease; 10-valent pneumococcal NTHi Protein D conjugate vaccine; vaccine efficacy; outer membrane protein; acute otitis media; investigational tetravalent Neisseria meningitidis serogroups A, C, W-135 and Y tetanus toxoid-conjugate vaccine; pneumococcal otitis efficacy trial; 11-valent PCV with all serotypes conjugated to Protein D; combined diphtheria–tetanus–acellular pertussis–hepatitis B-inactivated poliovirus– Haemophilus influenzae type b vaccine; group that did not receive prophylactic paracetamol; non-typeable H. influenzae; group that received prophylactic paracetamol; confidence intervals; middle ear fluid; optical density; standard deviation; Pasteurellaceae; Streptococcaceae; Booster vaccination; Bacteria; Micrococcales; Protein
• ISSN: 0264-410X; 1873-2518; 1873-2518
• DOI: 10.1016/j.vaccine.2010.12.086

Pneumococcal conjugate vaccines (PCV) may reduce nasopharyngeal carriage (NPC) of Streptococcus pneumoniae vaccine strains (VT), but serotype replacement with non-vaccine strains (NVT) has been reported. Bacterial NPC after PHiD-CV vaccination was assessed in the second year of life. Open descriptive study of NPC reported for 414 subjects vaccinated at 3–5 and 12–15 months of age with PHiD-CV with or without prophylactic paracetamol (PP) compared to 336 age-matched PCV-naïve controls. Carriage was assessed prior to and 1, 3, 7 and 12 months after PHiD-CV booster or MenACWY-TT control vaccination at 12–15 months of age. At each visit, carriage of VT was reduced by 22–35% in PHiD-CV recipients. Vaccine efficacy across all visits was 21.7% [95% CI 2.6; 37.0] (26.8% carriage in the PHiD-CV group versus 34.2% in controls). Carriage rates of NVT tended to be higher in PHiD-CV recipients. Pre-booster, these findings were more pronounced when PP had not been administered. No substantial effect of PHiD-CV vaccination was observed on NPC of other bacterial pathogens including non-typeable Haemophilus influenzae. Primary and booster vaccination with PHiD-CV reduced NPC of VT in the second year of life and tended to slightly increase that of NVT in line with previous experience with the 7-valent PCV.